BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25921399)

  • 1. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D; Karle CA; Kiehn J
    Curr Pharm Des; 2006; 12(18):2271-83. PubMed ID: 16787254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
    Taboureau O; Jørgensen FS
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interactions between hERG potassium channel and blockers.
    Du L; Li M; You Q
    Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational investigations of hERG channel blockers: New insights and current predictive models.
    Villoutreix BO; Taboureau O
    Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
    Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
    Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
    Thai KM; Ecker GF
    Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
    Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
    Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
    Moorthy NS; Ramos MJ; Fernandes PA
    SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.